Table 1.
Characteristics of the studies included in the systematic review and network meta-analysis
| First author | Publication year | Country | Final follow-up (m) | Outcomes | Treatment | Total patients (n) | Male (n) | Female (n) | Mean age (years) | |
|---|---|---|---|---|---|---|---|---|---|---|
| Arik (13) | 2014 | Turkey | 6 | VAS, PRTEE | AB | 40 | 11 | 29 | 43.7 | |
| CS | 40 | 10 | 30 | 46.7 | ||||||
| Branson (36) | 2017 | Australia | 6 | PRTEE | AB | 14 | 10 | 4 | 47.9 | |
| CS | 14 | 8 | 6 | 48.1 | ||||||
| Coombes (14) | 2013 | Australia | 12 | VAS, PRTEE | CS | 43 | 27 | 16 | 49.3 | |
| PL | 41 | 14 | 17 | 49.9 | ||||||
| Creaney (37) | 2011 | UK | 6 | PRTEE | PRP | 63 | 36 | 27 | 53.0 | |
| AB | 48 | 27 | 21 | 48.0 | ||||||
| Creuzé (15) | 2018 | France | 3 | VAS, GS | BT | 30 | 17 | 13 | 47.3 | |
| PL | 30 | 16 | 14 | 46.7 | ||||||
| Dojode (16) | 2012 | India | 6 | VAS, MNS | AB | 30 | 13 | 17 | 42.9 | |
| CS | 30 | 12 | 18 | 42.2 | ||||||
| Espandar (17) | 2010 | Iran | 4 | VAS, GS | BT | 24 | 2 | 22 | 43.3 | |
| PL | 24 | 2 | 22 | 44.2 | ||||||
| Gautam (18) | 2015 | India | 6 | VAS, DASH, GS | PRP | 15 | NA | NA | NA | |
| CS | 15 | NA | NA | NA | ||||||
| Gosens (19) | 2011 | Netherlands | 24 | VAS | PRP | 51 | 23 | 28 | 46.8 | |
| CS | 49 | 23 | 26 | 47.3 | ||||||
| Guo (20) | 2017 | Taiwan | 4 | VAS, PRTEE, GS | BT | 15 | 6 | 9 | 49.9 | |
| CS | 11 | 5 | 6 | 53.4 | ||||||
| Gupta (21) | 2020 | India | 12 | VAS, DASH, GS | PRP | 40 | NA | NA | 42.4 | |
| CS | 40 | NA | NA | 39.4 | ||||||
| Jindal (22) | 2013 | India | 1 | VAS, MNS | AB | 25 | 14 | 11 | 39.0 | |
| CS | 25 | 17 | 8 | 37.3 | ||||||
| Kazemi (23) | 2010 | Iran | 2 | VAS, MNS, DASH, GS | AB | 30 | 7 | 23 | 47.2 | |
| CS | 30 | 4 | 26 | 47.0 | ||||||
| Khaliq (24) | 2015 | Pakistan | 1 | VAS | PRP | 51 | 21 | 30 | 34.0 | |
| CS | 51 | 24 | 27 | 34.0 | ||||||
| Krogh (38) | 2013 | Denmark | 3 | PRTEE | PRP | 20 | 9 | 11 | 47.6 | |
| CS | 20 | 11 | 9 | 44.7 | ||||||
| PL | 20 | 9 | 11 | 43.9 | ||||||
| Lebiedziński (39) | 2015 | Poland | 12 | DASH | AB | 53 | 28 | 25 | 47.0 | |
| CS | 46 | 12 | 34 | 54.0 | ||||||
| Lin (25) | 2010 | Taiwan | 3 | VAS, GS | BT | 8 | 3 | 5 | 45.9 | |
| CS | 9 | 6 | 3 | 44.6 | ||||||
| Linnanmaki (26) | 2020 | Finland | 12 | VAS, DASH, GS | PRP | 40 | 18 | 22 | 46.0 | |
| AB | 40 | 20 | 20 | 46.0 | ||||||
| PL | 39 | 17 | 22 | 49.0 | ||||||
| Montalvan (27) | 2016 | France | 12 | VAS | PRP | 25 | 17 | 8 | 47.0 | |
| PL | 25 | 17 | 8 | 46.4 | ||||||
| Omar (28) | 2012 | Egypt | 1.5 | VAS, DASH | PRP | 15 | 6 | 9 | 40.5 | |
| CS | 15 | 5 | 10 | 37.5 | ||||||
| Ozturan (43) | 2010 | Turkey | 12 | GS | AB | 18 | 7 | 11 | 44.0 | |
| CS | 20 | 10 | 10 | 45.8 | ||||||
| Palacio (40) | 2016 | Brazil | 6 | PRTEE, DASH | PRP | 20 | NA | NA | 46.6 | |
| CS | 20 | NA | NA | 46.2 | ||||||
| Placzek (29) | 2007 | Germany | 4 | VAS | BT | 68 | 31 | 37 | 47.4 | |
| PL | 62 | 30 | 32 | 46.9 | ||||||
| Raeissadat (30) | 2014 | Iran | 12 | VAS | PRP | 31 | 8 | 23 | 43.0 | |
| AB | 30 | 6 | 24 | 44.0 | ||||||
| Schöffl (41) | 2017 | Germany | 6 | DASH | PRP | 18 | 9 | 9 | 52.6 | |
| PL | 18 | 9 | 9 | 52.6 | ||||||
| Singh (42) | 2013 | India | 3 | PRTEE | AB | 30 | 12 | 18 | 35.2 | |
| CS | 30 | 16 | 14 | 33.0 | ||||||
| Thanasas (31) | 2011 | Greece | 6 | VAS | PRP | 14 | NA | NA | 35.9 | |
| AB | 14 | NA | NA | 36.6 | ||||||
| Varshney (32) | 2017 | India | 6 | VAS | PRP | 33 | NA | NA | NA | |
| CS | 50 | NA | NA | NA | ||||||
| Wolf (33) | 2011 | USA | 6 | VAS, DASH | AB | 9 | NA | NA | NA | |
| CS | 9 | NA | NA | NA | ||||||
| PL | 10 | NA | NA | NA | ||||||
| Wong (34) | 2005 | China | 3 | VAS | BT | 30 | 5 | 25 | 45.0 | |
| PL | 30 | 6 | 24 | 44.2 | ||||||
| Yerlikaya (35) | 2018 | Turkey | 2 | VAS | PRP | 60 | 15 | 45 | 45.8 | |
| PL | 30 | 11 | 19 | 47.6 | ||||||
Abbreviations: VAS, visual analog score; DASH, Disabilities of Arm Shoulder and Hand score; MNS, modified Nirschl score; PRTEE, Patient-Related Tennis Elbow Evaluation score; GS, grip strength; CS, corticosteroid; AB, autologous blood; BT, botulinum toxin; PRP, platelet-rich plasma; PL, placebo